Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 14/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.47 |
| ▸ | TNNC1 | P63316 | 5/20 | 0.43 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.43 |
| ▸ | GPR183 | P32249 | 1/20 | 0.43 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11927165 | 1.00 | S1PR1 (0.55) | S1PR1L3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11927465 | 0.89 | S1PR1 (0.67) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL5559723 | 0.89 | S1PR1 (0.67) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL27625020 | 0.84 | S1PR1 (0.44) | S1PR1S1PR3TNNC1SGPL1S1PR4 | |
| SCHEMBL14593245 | 0.82 | S1PR1 (0.51) | S1PR1S1PR3TNNC1SGPL1S1PR4 | |
| SCHEMBL6529404 | 0.81 | S1PR1 (0.59) | S1PR1RAB9AS1PR3TNNC1SGPL1 | |
| SCHEMBL14593328 | 0.81 | SMN1; SMN2 (0.43) | S1PR1SMN1; SMN2S1PR3TNNC1SGPL1 | |
| SCHEMBL5397755 | 0.81 | SMN1; SMN2 (0.43) | S1PR1SMN1; SMN2S1PR3TNNC1SGPL1 | |
| SCHEMBL5566429 | 0.79 | S1PR1 (0.59) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL27625019 | 0.78 | S1PR1 (0.43) | S1PR1S1PR3TNNC1SGPL1S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1594508-B1 | NOVEL BICYCLIC COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2012-08-08 | — | — | EP | disclosed |
| US-7256206-B2 | 1-[4-(3-Amino-4-hydroxy-3-hydroxymethyl-butyl)-phenyl]-ethanone-O-biphenyl-4-ylmethyl-oxime, used as modulators of lipid activated G-protein coupled receptors specific for sphingosine-1-phosphate; prevention of autoimmune diseases or as angiogenesis inhibitors | IRM LLC (BM) | 2007-08-14 | — | — | US | disclosed |
| US-20040248952-A1 | Novel bicyclic compounds and compositions | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248952-A1 | Novel bicyclic compounds and compositions | S1PR1, S1PR3, S1PR5 | S1PR1 1/4885L3MBTL1 3502/4885NPC1 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.